Ares Capital Fell Enough to Push Its Yield Near 10%. Here's the Number That Actually Worries Me.

Ares Capital shares are down ~10% from their $22.51 52-week high to about $20, lifting the dividend yield to ~9.6% (near 10%). Non-accrual loans rose from 2.1% to 2.4% of total investments at amortized cost after adding four new non-accrual loans, which could pressure dividend coverage, especially since core earnings were $0.94/share vs $0.96/share dividend. The article is still constructive because the non-accrual rate remains below its ~3% historical average and realized gains have outpaced losses by $1B+ over 21 years, but it flags that a move above the historical average would be the key trigger to reconsider the position.

Analysis

This is more a credit-normalization signal than an idiosyncratic blowup. For ARCC, the immediate market issue is not the current loss bucket; it is whether recurring earnings can keep up with the distribution once the usual lagged effects of non-accrual migration and lower reinvestment income feed through over the next 1-2 quarters. The balance sheet cushion and realized-gain history reduce near-term dividend-cut odds, but they do not prevent multiple compression if investors start underwriting a slower path to coverage.

Relative value matters more than direction here. ARCC should remain one of the better-positioned public BDCs because scale and diversification blunt single-name default risk, while more concentrated peers like CSWC are more exposed to one-off credit events and NAV volatility if the environment keeps normalizing. A broader rise in BDC non-accruals would also tighten financing conditions for sponsor-backed borrowers, which can slow originations and fee growth across the private credit ecosystem; that is a second-order headwind for lower-quality lenders before it becomes a problem for ARCC.

The consensus may be overreacting to the count of problem loans and underweighting recoveries, portfolio seasoning, and the spillover-income buffer. What would falsify the bullish case is not another isolated non-accrual, but a sustained move above the historical loss-rate average combined with sequential NAV erosion and core EPS staying below the payout for multiple quarters. If that happens, the yield is no longer compensation but a warning.

Key Decisions for Investors

• Long ARCC on further weakness into the next 1-2 weeks as a carry trade, but only if shares hold near or below ~9.5-10.0x implied cash yield; target a 3-6 month rebound if non-accruals stabilize and core earnings stop deteriorating.
• Pair trade: long ARCC / short CSWC for 1-3 months. Thesis: the market should reward ARCC's diversification and balance-sheet resilience while penalizing more concentrated BDCs harder if credit normalizes further. Stop the pair if ARCC's non-accrual rate breaks above its historical average or CSWC reports improving credit trends.
• Avoid initiating an outright short in ARCC unless the next quarterly update shows another step-up in non-accruals plus a downward revision to core earnings guidance. The current signal is too mild for a clean bearish standalone position.
• Set an alert on ARCC core EPS coverage and NAV trend over the next two earnings prints. If coverage remains below the dividend and NAV is down sequentially for two quarters, shift from hold/long to reduce/exit.
• If you want sector exposure with less idiosyncratic risk, favor the highest-quality public BDCs over the basket until credit metrics stabilize; the next 1-3 months should separate diversified platforms from concentrated lenders.